Table 4.
Ribavirin plus conventional or pegylated interferon in the treatment of chronic hepatitis D
| Author | Case no. | HBeAg/HBV DNA(+) | Dose | EOT | EFU | ||
|---|---|---|---|---|---|---|---|
| VR | BR | VR | BR | ||||
| Kaymakoglu [48], Turkey | 19 | 0/0 | IFN-α2b 10 MU tiw + RBV 1,000–1,200 mg daily ×24 M | 8 (42%) | 8 (42%) | 4 (21%) | 7 (37%) |
| Gunsar [47], Turkey | 31 | 0/0 | IFN-α2a 9 MU tiw ×24 M (n = 10) | 5 (50%) | 6 (60%) | 2 (20%) | 2 (20%) |
| IFN + RBV 1,000–1,200 mg daily ×24 M (n = 21) | 11 (52%) | 12 (57%) | 5 (24%) | 5 (24%) | |||
| Niro [46], Italy | 38 | NA/2 (13%) | PegIFN-α2b 1.5 μg/kg/W ×72 W (n = 16) | 3 (19%) | 6 (38%) | 4 (25%) | 4 (25%) |
| NA/5 (23%) | PegIFN ×72 W + RBV 800 mg daily ×48 W (n = 22) | 2 (9%) | 9 (41%) | 4 (18%) | 6 (27%) | ||
Note: VR, virological response; BV, biochemical response; EOT, end of treatment; EFU, end of follow-up; NA, not available; IFN, interferon; PegIFN, pegylated interferon; MU, mega-unit; RBV, ribavirin; W, week; M, month